ABIVAX Société Anonyme (EPA:ABVX)

France flag France · Delayed Price · Currency is EUR
70.90
-0.60 (-0.84%)
Sep 25, 2025, 9:09 AM CET
-0.84%
Market Cap5.40B
Revenue (ttm)6.02M
Net Income (ttm)-195.39M
Shares Out75.57M
EPS (ttm)-3.09
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,706
Average Volume106,039
Open70.40
Previous Close71.50
Day's Range70.00 - 71.00
52-Week Range4.51 - 78.70
Beta0.13
RSI61.87
Earnings DateDec 15, 2025

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 69
Stock Exchange Euronext Paris
Ticker Symbol ABVX
Full Company Profile

Financial Performance

In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.

Financial Statements

News

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

1 day ago - GlobeNewsWire

New Option Listings Announced for Abivax (ABVX)

New Option Listings Announced for Abivax (ABVX)

6 days ago - GuruFocus

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX)...

12 days ago - GlobeNewsWire

BTIG Reiterates Buy Rating on Abivax (ABVX) with $112 Price Target | ABVX Stock News

BTIG Reiterates Buy Rating on Abivax (ABVX) with $112 Price Target | ABVX Stock News

15 days ago - GuruFocus

Abivax SA (ABVX) Reports First Half 2025 Financial Results | ABVX stock news

Abivax SA (ABVX) Reports First Half 2025 Financial Results | ABVX stock news

16 days ago - GuruFocus

Abivax Presents First Half 2025 Financial Results

Abivax Presents First Half 2025 Financial Results PARIS, France, September 8, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a cli...

16 days ago - GlobeNewsWire

Abivax (ABVX) Gains on Takeover Speculation

Abivax (ABVX) Gains on Takeover Speculation

19 days ago - GuruFocus

Abivax jumps amid takeover speculation

19 days ago - Seeking Alpha

Abivax (ABVX) Surges Following Positive Trial Data, Boosts Hedge Funds

Abivax (ABVX) Surges Following Positive Trial Data, Boosts Hedge Funds

24 days ago - GuruFocus

Abivax’s 580% surge hands biotech hedge funds a rare 2025 win

Abivax’s 580% surge hands biotech hedge funds a rare 2025 win

24 days ago - Seeking Alpha

How Hedge Funds Won Big on an Obscure Drugmaker

Results of a Paris company's late-stage drug trial helped turn things around for healthcare-focused funds, which struggled in the first half of the year.

25 days ago - WSJ

2 Logical Mid-Cap Biotech Buyout Targets

There have been some significant acquisitions in the mid-cap biotech space over the past couple of months. In today's column, I highlight two mid-cap biotech names that should have bright futures on t...

4 weeks ago - Seeking Alpha

Earnings Outlook For Abivax

Abivax (NASDAQ: ABVX) is set to give its latest quarterly earnings report on Monday, 2025-08-11. Here's what investors need to know before the announcement. Analysts estimate that Abivax will report ...

6 weeks ago - Benzinga

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Closing of $747.5 Million Public Offering PARIS, France, July 28, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-st...

2 months ago - GlobeNewsWire

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing ...

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) | ABVX Stock News

2 months ago - GuruFocus

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

2 months ago - GlobeNewsWire

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or t...

2 months ago - GlobeNewsWire

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Compan...

2 months ago - GlobeNewsWire

Abivax launches $400M ADS offering

2 months ago - Seeking Alpha

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Co...

2 months ago - GlobeNewsWire

Abivax Announces Launch of Public Offering

Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnolog...

2 months ago - GlobeNewsWire

Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 350 points on Wednesday. The Dow traded up 0.82% to 44,869.16 while the NASDAQ rose 0.16% to 20,925.86. The...

2 months ago - Benzinga